Eloxx Pharmaceuticals, Inc. ELOX
We are a clinical-stage biopharmaceutical company developing novel, small molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations ("NMs") to enable the production of full-length proteins. Targeting ribosome subunits provides a therapeutic approach to addressing a number of genetic diseases. According to the Human Gene Mutation Database, NMs account for approximately 10% to 12% of patients with a given genetic disease. There are over 7,000 inherited genetic diseases that collectively affect 350 million people worldwide. Our immediate focus is to advance the clinical development of our lead product candidate, exaluren, for the treatment of rare kidney diseases and, through our collaboration with Almirall, S.A. ("Almirall"), ZKN-013 for the treatment of rare skin diseases.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $6.4M | $0 | — | — | — | — | — | — | — |
| R&D | — | — | — | — | — | $14.6M | $26.3M | $20.5M | $16.4M | $9.0M |
| SG&A | $3.4M | $5.2M | $8.7M | $10.7M | $20.4M | $14.8M | $24.2M | $26.5M | $2.7M | $854.0K |
| Total operating expenses | $6.4M | $8.8M | $17.3M | $34.4M | $66.0M | $33.5M | $50.6M | $47.6M | $20.4M | $9.8M |
| Operating income | -$6.4M | -$2.5M | -$17.3M | -$34.4M | -$66.0M | -$33.5M | -$50.6M | -$47.6M | -$20.4M | -$9.8M |
| Pre-tax income | -$6.0M | -$3.1M | -$17.1M | -$36.1M | -$66.7M | -$34.6M | -$50.9M | -$47.1M | -$21.2M | -$9.8M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $122.0K | $1.0M | $680.0K |
| Net income | -$6.0M | -$3.1M | -$17.1M | -$36.1M | -$66.7M | -$34.6M | -$50.9M | -$47.2M | -$21.2M | -$9.8M |
| EPS, basic | -5.34 | -9.20 | -72.98 | -16.65 | -38.15 | — | — | — | — | — |
| EPS, diluted | -5.34 | -9.20 | -72.98 | -16.65 | -38.15 | -0.86 | -1.34 | -1.45 | -4.75 | -2.60 |
| Shares, diluted (wtd. avg.) | 1.1M | 341,708 | 233,670 | 2.2M | 1.7M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.8M | $111.0K | $1.1M | $19.2M | $42.3M | $24.7M | $22.5M | $48.6M | $24.0M | $2.2M |
| Short-term investments | — | — | — | — | — | — | $33.8M | — | — | — |
| Total current assets | $5.3M | $3.0M | $1.5M | $20.1M | $43.5M | $25.9M | $57.7M | $50.3M | $24.5M | $3.1M |
| Property, plant and equipment | $0 | $0 | $35.0K | $169.0K | $216.0K | $133.0K | $201.0K | $248.0K | $278.0K | $41.0K |
| Goodwill | — | — | — | — | — | — | — | — | — | $0 |
| Total assets | $5.3M | $3.0M | $1.7M | $21.1M | $45.1M | $26.5M | $58.9M | $50.7M | $24.8M | $3.1M |
| Accounts payable | $2.7M | $5.3M | $5.7M | $3.0M | $1.4M | $481.0K | $1.9M | $747.0K | $1.5M | $1.9M |
| Short-term debt | $1.0M | $6.5M | $2.2M | $4.0M | $0 | $5.2M | $4.3M | — | — | — |
| Total current liabilities | $17.2M | $27.3M | $22.7M | $23.1M | $10.0M | $9.8M | $11.8M | $7.8M | $3.4M | $2.5M |
| Long-term debt | $0 | $0 | $1.6M | $8.6M | $12.0M | $6.4M | $10.5M | — | — | — |
| Total liabilities | $17.2M | $27.3M | $24.3M | $31.8M | $22.8M | $16.2M | $22.7M | $7.8M | $5.0M | $4.7M |
| Retained earnings | -$300.6M | -$294.6M | -$291.4M | -$274.4M | -$238.3M | -$171.6M | -$137.0M | -$86.1M | -$39.0M | -$17.7M |
| Total equity | -$11.9M | -$24.3M | -$22.6M | -$10.7M | $22.4M | $10.2M | $36.2M | $42.9M | $21.4M | $610.0K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.3M | -$4.7M | -$14.3M | -$31.8M | -$35.0M | -$28.2M | -$39.4M | -$31.4M | -$15.9M | -$8.8M |
| Depreciation and amortisation | $0 | $35.0K | $113.0K | $77.0K | $114.0K | $68.0K | $87.0K | $216.0K | $39.0K | $8.0K |
| Stock-based compensation | $235.0K | $541.0K | $2.0M | $3.0M | $9.2M | $8.7M | $11.3M | $13.4M | $101.0K | $78.0K |
| Capital expenditure | — | — | — | $66.0K | $89.0K | — | $40.0K | $235.0K | $237.0K | $36.0K |
| Investing cash flow | $1.0K | $38.0K | $309.0K | -$66.0K | $2.1M | $33.8M | -$33.5M | -$317.0K | -$114.0K | -$36.0K |
| Financing cash flow | $11.0M | $3.4M | -$4.1M | $8.8M | $50.8M | -$3.4M | $46.8M | $56.2M | $38.0M | $9.7M |
| Dividends paid | — | — | — | — | — | — | $0 | $0 | $0 | — |
| Buybacks | — | — | — | — | — | — | — | $31.0K | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-257750.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $0 | $6.4M | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$9.8M | -$21.2M | -$47.2M | -$50.9M | -$34.6M | -$66.7M | -$36.1M | -$17.1M | -$3.1M | -$6.0M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Officer or director change Item 5.02
- Officer or director change Item 5.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Officer or director change Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |